CHF: Major News and Trial Updates in CHF in 2023

https://is1-ssl.mzstatic.com/image/thumb/Podcasts122/v4/82/43/b7/8243b73b-2d11-1311-21be-68683a295068/mza_12804423687283069731.jpg/600x600bb.jpg

'Why we do What we do in Cardiology'

Bishnu Subedi

35 episodes

1 week ago

I am Dr. Bishnu Subedi. I am a cardiologist in the United States. In the era of evidence-based medicine, our practice is usually guided by a scientific study, expert society statements, or clinical guidelines. In this podcast series, I intend to highlight some of these practice-changing articles in the field of cardiology from past and present.

Medicine

Health & Fitness

RSS

All content for 'Why we do What we do in Cardiology' is the property of Bishnu Subedi and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Medicine

Health & Fitness

https://d3t3ozftmdmh3i.cloudfront.net/production/podcast_uploaded_nologo/5443800/5443800-1710051687903-3d02caa2ebc39.jpg

CHF: Major News and Trial Updates in CHF in 2023

'Why we do What we do in Cardiology'

4 minutes 25 seconds

1 year ago

CHF: Major News and Trial Updates in CHF in 2023

A quick rundown of the key developments:

Trials:

STEP-HFpEF
CASTLE-HTx
HEART FID
DAPA-MI

Policy and Guidelines:

ESC cardiomyopathy guidelines
Inflation Reduction Act
FDA approvals: dapagliflozin and sotagliflozin

Other Highlights:

The world's second-living patient with end-stage heart failure received a genetically modified pig heart transplant but sadly died after 6 weeks due to transplant rejection.
The ARIES-HCM3 trial
The PUSH AHF trial
The QUEST trial from China
Declining interest in advanced heart failure and transplant cardiology fellowships